Gateway Investment Advisers LLC Nektar Therapeutics Transaction History

Gateway Investment Advisers LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 15, 2019	SELL	$16.91 - $36.27 $116,137 - $249,102	-6,868 Closed	0 $0
Q4 2018 Jan 14, 2019	BUY	$30.43 - $56.65 $395 - $736	13 Added 0.19%	6,868 $226,000
Q3 2018 Oct 16, 2018	SELL	$46.46 - $68.49 $6,457 - $9,520	-139 Reduced 1.99%	6,855 $418,000
Q2 2018 Jul 11, 2018	SELL	$46.25 - $104.45 $33,022 - $74,577	-714 Reduced 9.26%	6,994 $342,000
Q1 2018 Apr 12, 2018	BUY	$57.4 - $108.44 $442,439 - $835,855	7,708 New	7,708 $819,000

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Gateway Investment Advisers LLC with notifications on news.